Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFRi) are
approved for treating EGFR-mutant lung adenocarcinoma (LUAD), emergence of acquired …

Abnormal activation of epidermal growth factor receptor (EGFR) drives non-small cell lung
cancer (NSCLC) development. EGFR mutations-mediated resistance to tyrosine-kinase …

Lung cancer is the leading cause of cancer‐related deaths worldwide. Lung
adenocarcinomas (LUADs) are a major subtype of non‐small‐cell lung cancers (NSCLCs) …

Lung cancer is treated with many conventional therapies, such as surgery, radiation, and
chemotherapy. However, these therapies have multiple undesirable side effects. To bypass …

Activating mutations in the epidermal growth factor receptor (EGFR) are common driver
mutations in non-small cell lung cancer (NSCLC). First, second and third generation EGFR …

Background The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine
kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not …

Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI), is an
effective treatment for non‐small‐cell lung cancer (NSCLC) with EGFR activating mutations …

PURPOSE Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) show
efficacy in treating patients with lung adenocarcinoma with EGFR-activating mutations …

Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression
but it is invariably followed by drug resistance. In characterizing early transcriptional …

Lung cancer is the leading cause of cancer-related deaths worldwide. Fibroblast growth
factor receptor 1 (FGFR1) gene amplification is one of the most prominent and potentially …